Alström综合征与BMI匹配对照者的内分泌代谢综合评估
本研究纳入38例Alström综合征(AS)患者(2至38岁)并与76名按年龄、性别、种族和BMI匹配的对照者(2至48岁)比较,进行空腹生化、混合膳食试验、间接测热法、双能X线吸收法和MRI/磁共振波谱检查。结果显示AS患者严重胰岛素抵抗和2型糖尿病突出,且可伴有影响生长发育的多种其他内分泌疾病。
要点
- AS患者中肥胖占76%、2型糖尿病占37%、甲状腺功能减退占29%、中枢性肾上腺功能不全占3%。
- 成人性腺功能减退占57%(三分之一为中枢性,三分之二为原发性),女性高雄激素血症占25%。
- AS患者胰岛素抵抗指数、混合膳食试验血糖、胰岛素和C肽、HbA1c及2型糖尿病患病率均高于对照。
核心结论
- 严重胰岛素抵抗和2型糖尿病是Alström综合征的标志,但患者可能伴有影响生长发育的多种其他内分泌疾病。
研究设计与样本
- 研究纳入38例Alström综合征患者(年龄2至38岁),按年龄、性别、种族和BMI与76名对照者(年龄2至48岁)匹配。
- 检测包括空腹生化、混合膳食试验、间接测热法、双能X线吸收法和MRI/磁共振波谱。
主要发现
- AS患者中肥胖占76%,2型糖尿病占37%,甲状腺功能减退占29%(三分之一为中枢性,三分之二为原发性),中枢性肾上腺功能不全占3%。
- 成人性腺功能减退占57%(三分之一为中枢性,三分之二为原发性),女性高雄激素血症占25%。
- AS患者与对照者的BMI z评分、体脂、腰围、腹部内脏脂肪、肌肉脂肪、调整瘦体重的静息能量消耗、游离脂肪酸、胰高血糖素、催乳素、ACTH和皮质醇相似。
- 与对照相比,AS患者身高更矮且IGF-1浓度更低(P≤0.001)。
- AS患者空腹及混合膳食试验胰岛素抵抗指数显著更高,混合膳食试验血糖、胰岛素和C肽值更高,HbA1c更高,2型糖尿病患病率更高(P<0.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Alström syndrome (AS), a monogenic form of obesity, is caused by recessive mutations in the centrosome- and basal body-associated gene ALMS1. AS is characterized by retinal dystrophy, sensory hearing loss, cardiomyopathy, childhood obesity, and metabolic derangements. OBJECTIVE: We sought to characterize the endocrine and metabolic features of AS while accounting for obesity as a confounder by comparing patients with AS to body mass index (BMI)-matched controls. METHODS: We evaluated 38 patients with AS (age 2 to 38 years) who were matched with 76 controls (age 2 to 48 years) by age, sex, race, and BMI. Fasting biochemistries, mixed meal test (MMT), indirect calorimetry, dual-energy X-ray absorptiometry, and MRI/magnetic resonance spectroscopy were performed. RESULTS: Frequent abnormalities in AS included 76% obesity, 37% type 2 diabetes mellitus (T2DM), 29% hypothyroidism (one-third central, two-thirds primary), 3% central adrenal insufficiency, 57% adult hypogonadism (one-third central, two-thirds primary), and 25% female hyperandrogenism. Patients with AS and controls had similar BMI z scores, body fat, waist circumference, abdominal visceral fat, muscle fat, resting energy expenditure (adjusted for lean mass), free fatty acids, glucagon, prolactin, ACTH, and cortisol. Compared with controls, patients with AS were shorter and had lower IGF-1 concentrations (Ps ≤ 0.001). Patients with AS had significantly greater fasting and MMT insulin resistance indices, higher MMT glucose, insulin, and C-peptide values, higher HbA1c, and higher prevalence of T2DM (Ps < 0.001). Patients with AS had significantly higher triglycerides, lower high-density lipoprotein cholesterol, and a 10-fold greater prevalence of metabolic syndrome (Ps < 0.001). Patients with AS demonstrated significantly greater liver triglyceride accumulation and higher transaminases (P < 0.001). CONCLUSION: Severe insulin resistance and T2DM are the hallmarks of AS. However, patients with AS may present with multiple other endocrinopathies affecting growth and development.
引用
- Han JC, Reyes-Capo DP, Liu CY, et al. Comprehensive Endocrine-Metabolic Evaluation of Patients With Alström Syndrome Compared With BMI-Matched Controls. J Clin Endocrinol Metab. 2018. PMID: 29718281. doi:10.1210/jc.2018-00496
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。